Intelligent Bio Solutions 대차 대조표 상태

재무 상태 기준 확인 4/6

Intelligent Bio Solutions 의 총 주주 지분은 $5.9M 이고 총 부채는 $499.6K, 이는 부채 대 자기자본 비율을 8.4% 로 가져옵니다. 총자산과 총부채는 각각 $11.7M 및 $5.8M 입니다.

주요 정보

8.4%

부채 비율

US$499.61k

부채

이자 보상 비율	n/a
현금	US$3.99m
주식	US$5.95m
총 부채	US$5.78m
총 자산	US$11.73m

최근 재무 상태 업데이트

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Jul 29

Recent updates

재무 상태 분석

단기부채: INBS 의 단기 자산 ( $6.5M )이 단기 부채( $5.7M ).

장기 부채: INBS 의 단기 자산( $6.5M )이 장기 부채( $97.8K ).

부채 대 자본 내역 및 분석

부채 수준: INBS 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: INBS 은 5년 전에 마이너스 주주 지분을 가졌으나 지금은 플러스이므로 개선되었습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: INBS 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 12.9 %의 역사적 비율로 계속 감소할 경우 INBS 의 현금 활주로는 1년 미만입니다.

Intelligent Bio Solutions 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’ Equity Requirement

Intelligent Bio Solutions Provides Nasdaq Compliance Update

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Recent updates

Intelligent Bio Solutions Inc. Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission

First quarter 2025 earnings released: US$0.70 loss per share (vs US$12.49 loss in 1Q 2024)

Intelligent Bio Solutions Inc. Provides Revenue Guidance for the First Quarter Ended September 30, 2024

GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(K) Submission

New major risk - Revenue and earnings growth

New major risk - Share price stability

Intelligent Bio Solutions Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

Intelligent Bio Solutions Inc. Announces the Successful Completion of Biocompatibility Testing of Its Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Inc. Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology

Forecast to breakeven in 2026

Intelligent Bio Solutions Inc. Announces Board Changes

Intelligent Bio Solutions Inc. Completes Recruitment and Begins Subject Screening for FDA 510(K) Pharmacokinetic Study

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Intelligent Bio Solutions Inc. announced that it has received $10.116165 million in funding

Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’ Equity Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Intelligent Bio Solutions Inc. Provides Unaudited Preliminary Earnings Guidance for the Second Quarter and Six Months Ended December 31, 2023

Intelligent Bio Solutions Provides Nasdaq Compliance Update

Intelligent Bio Solutions Receives NATA Accreditation for Its Revolutionary Fingerprint Sweat Drug Screening System

Intelligent Bio Solutions Inc., Annual General Meeting, Dec 13, 2023

New minor risk - Profitability

New major risk - Share price stability

Intelligent Bio Solutions Inc. Debuts Intelligent Fingerprinting Drug Screening Solution At the 2023 Workplace Health & Safety Show in Sydney, Australia

Intelligent Bio Solutions Inc. Completes Critical Development Milestone in Plans to Add Ketamine and Tramadol to Fingerprint Drug Test

Consensus EPS estimates fall by 32%

Price target decreased by 18% to US$11.30

Forecast to breakeven in 2026

Consensus revenue estimates increase by 19%, EPS downgraded

Consensus revenue estimates decrease by 21%

Consensus revenue estimates decrease by 39%

Intelligent Bio Solutions Inc. Files FDA 513(g) Regulatory Submission for Intelligent Fingerprinting Drug Screening Cartridge

Intelligent Bio Solutions Inc. Announces It Has Successfully Completed the Review of Results from Milestone 7

Intelligent Bio Solutions Inc. announced that it has received $0.220578 million in funding

Intelligent Bio Solutions Inc., Annual General Meeting, Feb 08, 2023

High number of new directors

Intelligent Bio Solutions Inc. to Report Q1, 2023 Results on Nov 09, 2022

High number of new directors

Intelligent Bio Solutions Inc. Elects Harry Simeonidis as the Company’s President Effective as of October 26, 2022

GBS Inc. Announces Board Appointments

GBS Inc. (NasdaqCM:GBS) acquired Intelligent Fingerprinting Limited.

GBS acquires Intelligent Fingerprinting in all-stock deal

GBS GAAP EPS of -$0.57, revenue of $0.44M

GBS Inc. to Report Q4, 2022 Results on Aug 31, 2022

High number of new directors

GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood

GBS Inc. (NasdaqCM:GBS) entered into a exclusive agreement to acquire Intelligent Fingerprinting Limited.

GBS Inc., Annual General Meeting, Jun 16, 2022

GBS Inc. to Report Q3, 2022 Results on May 10, 2022

GBS Inc. Announces Resignation of Leon Kempler as Member of the Board

High number of new and inexperienced directors

GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial At Sutter Health Mills-Peninsula Medical Center

Gbs Inc. Announces Resignation of Prof. Jonathan Sessler, A Member of the Board of Directors

No longer forecast to breakeven

GBS Inc. to Report Q2, 2022 Results on Feb 10, 2022

Gbs Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test

GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study

High number of new directors

GBS Inc.: Can Its Technology Come Through?

GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기